Report Description Table of Contents How Are Rising Diagnosis Rates, Severe Muscle Weakness, and Long-Term Treatment Needs Shaping the Necrotizing Autoimmune Myositis Market? The Global Necrotizing Autoimmune Myositis Market was estimated at USD 692.0 million in 2025 and is projected to reach USD 1,257.6 million by 2032, expanding at a CAGR of 8.91% during 2026–2032, according to Strategic Market Research. Necrotizing Autoimmune Myositis is a rare disease in which the body's immune system mistakenly attacks and damages healthy muscle cells. The Necrotizing Autoimmune Myositis Market addresses a rare patient population requiring specialized diagnosis and long-term treatment. A U.S. study published by Mayo Clinic in 2022 reported a disease prevalence of 1.85 cases per 100,000 adults aged 50 and older in Olmsted County, Minnesota, based on historical patient records. Although a reliable national or global patient total remains unavailable, a 2025 UK–Australian study identified 109 patients with anti-HMGCR immune-mediated necrotizing myopathy (IMNM), confirming the disease's presence across multiple geographic populations. Treatment utilization represents an important source of recurring healthcare demand. The 2025 international study reported that 96.7% of 91 patients with immunosuppressive treatment data received prednisolone, while 72.5% received methotrexate. Among 105 patients with relevant treatment records, 45.7% received intravenous immunoglobulin (IVIG) and 17.1% received rituximab. Emerging treatment technologies are creating opportunities in the Necrotizing Autoimmune Myositis Market. FcRn-targeting therapies and CD19-directed CAR T-cell therapies are being investigated as potential treatment options for patients with severe disease. These developments are expanding research into disease-specific treatments, although some approaches remain investigational. Overall, the market's long-term revenue potential depends on earlier diagnosis, sustained demand for immunoglobulin and immunosuppressive therapies, improved reimbursement, and successful regulatory approval of targeted treatments. Increasing clinical evidence supporting disease-specific therapies could gradually shift treatment expenditure toward higher-value biologics while addressing persistent muscle weakness and treatment resistance. Which Segments Lead the Necrotizing Autoimmune Myositis Market, and Where Are the Fastest-Growing Opportunities Emerging? By Disease Type: Anti-HMGCR Leads Revenue While Seronegative Recognition Broadens Treatment Demand Largest Subsegment: Anti-HMGCR — Statin-Associated Disease Recognition Supports Treatment Revenue Anti-HMGCR-associated immune-mediated necrotizing myopathy represents the largest modeled disease category in the global Necrotizing Autoimmune Myositis Market, accounting for approximately 55% of the total market, valued at USD 380.60 million in 2025, with a projected CAGR of 8.04% during 2026–2032. Anti-HMGCR autoantibodies serve as both a defining diagnostic biomarker and a key pathogenic factor in muscle fiber necrosis. Persistent muscle weakness, elevated creatine kinase levels, and the potential need for prolonged immunosuppressive therapy contribute to sustained clinical management and treatment expenditure. Fastest-Growing Subsegment: Seronegative IMNM — Diagnostic Recognition Expands the Identifiable Patient Population Seronegative Immune-Mediated Necrotizing Myopathy (IMNM) is a distinct subtype of necrotizing autoimmune myositis characterized by the absence of recognized myositis-specific autoantibodies, particularly anti-HMGCR and anti-SRP. Within the global Necrotizing Autoimmune Myositis Market, seronegative IMNM accounted for an estimated 10% market share, valued at USD 69.20 million in 2025, and is projected to register the fastest CAGR of 10.54% during 2026–2032. Diagnostic complexity, increased recognition of antibody-negative cases, and greater utilization of immunosuppressive therapies are expected to support market expansion. By Treatment Type: IVIG Anchors Spending as Targeted Biologics Gain Momentum Largest Subsegment: IVIG Therapy — Repeated Infusions Sustain High-Value Treatment Expenditure Intravenous immunoglobulin (IVIG) therapy holds the largest share of the Necrotizing Autoimmune Myositis Market, accounting for approximately 43% and USD 297.56 million in 2025, with an anticipated CAGR of 8.87% during 2026–2032. IVIG is widely used as a first-line or adjunct immunomodulatory treatment for immune-mediated necrotizing myopathy (IMNM), particularly in patients with severe muscle weakness or inadequate responses to corticosteroids. Its ability to improve muscle strength, reduce elevated muscle enzyme levels, and support steroid-sparing treatment strategies reinforces its clinical importance. Fastest-Growing Subsegment: Biologic Therapy — Targeted Treatments Could Reshape Future Revenue Biologic therapy accounts for an estimated 18% share of the Necrotizing Autoimmune Myositis Market, valued at USD 124.56 million in 2025, and is projected to register the fastest CAGR of 13.87% during 2026–2032. Biologic treatments target specific immune pathways responsible for muscle inflammation and damage, particularly in patients with immune-mediated necrotizing myopathy (IMNM) who respond inadequately to corticosteroids or conventional immunosuppressants. Increasing use of rituximab in refractory cases and growing clinical interest in targeted immunotherapies are expected to support further adoption. By Drug Class: Immunoglobulins Lead While Monoclonal Antibodies Open New Treatment Paths Largest Subsegment: Immunoglobulins — Established Clinical Utilization Supports Market Leadership Immunoglobulins accounted for the largest estimated share of the Necrotizing Autoimmune Myositis Market at 43%, representing USD 297.56 million in 2025, with a projected CAGR of 8.87% during 2026–2032. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) play important roles in immunomodulatory treatment, particularly among patients with anti-HMGCR or anti-SRP antibodies. IVIg is frequently administered as a first-line or add-on therapy to control immune-mediated muscle damage, improve muscle strength, and support treatment outcomes in patients with severe or refractory disease. Fastest-Growing Subsegment: Monoclonal Antibodies — Antibody-Targeted Therapies Expand Treatment Opportunities Monoclonal antibodies are gaining importance in the Necrotizing Autoimmune Myositis Market, particularly for patients with immune-mediated necrotizing myopathy (IMNM) who respond inadequately to corticosteroids and conventional immunosuppressants. Monoclonal antibodies accounted for an estimated 18% market share, valued at USD 124.56 million in 2025, and are projected to register the fastest CAGR of 13.87% during 2026–2032. Their expanding clinical role is associated with targeted immune modulation, particularly rituximab-based treatment approaches for refractory cases, where persistent muscle weakness and disease activity require additional therapeutic intervention. By Diagnosis: Autoantibody Testing Sharpens Patient Identification and Treatment Selection Largest and Fastest-Growing Subsegment: Autoantibody Testing — Precision Diagnosis Supports Earlier Treatment Decisions Autoantibody testing holds the largest estimated share of 38% in the Necrotizing Autoimmune Myositis Market, valued at USD 262.96 million in 2025, and is projected to register the fastest CAGR of 11.02% during 2026–2032. Its leading position reflects the clinical importance of detecting anti-SRP and anti-HMGCR antibodies, which help confirm immune-mediated necrotizing myopathy, differentiate disease subtypes, and guide treatment decisions. Increasing emphasis on antibody-based diagnosis, early disease identification, and personalized immunosuppressive therapy strengthens its role in clinical evaluation and disease management. By Route of Administration: Intravenous Therapies Lead While Subcutaneous Delivery Expands Treatment Flexibility Largest Subsegment: Intravenous — IVIG and Hospital-Based Treatment Drive Administration Revenue Intravenous administration holds the largest share of the global Necrotizing Autoimmune Myositis Market, accounting for approximately 60% in 2025, valued at USD 415.20 million, and is projected to grow at a CAGR of 9.51% during 2026–2032. Intravenous immunoglobulin (IVIG) remains a key treatment for immune-mediated necrotizing myopathy (IMNM), particularly among patients with severe muscle weakness or inadequate responses to corticosteroids. IVIG therapy helps improve muscle strength, reduce creatine kinase levels, control immune-mediated muscle damage, and minimize long-term corticosteroid dependence. Fastest-Growing Subsegment: Subcutaneous — Emerging Biologic Delivery Creates New Treatment Opportunities Subcutaneous administration accounted for an estimated 4% of the global Necrotizing Autoimmune Myositis Market, valued at USD 27.68 million in 2025, and is projected to register the fastest CAGR of 17.51% during 2026–2032. Subcutaneous immunoglobulin (SCIG) is emerging as an effective, well-tolerated alternative to intravenous immunoglobulin (IVIG) for maintenance therapy and selected induction treatments in immune-mediated necrotizing myopathy (IMNM). Its potential for home-based administration, reduced dependence on hospital infusion services, and greater treatment flexibility supports wider adoption among patients requiring long-term immunoglobulin therapy. By End User: Hospital Expertise Leads Revenue While Infusion Centers Build Outpatient Capacity Largest Subsegment: Hospitals — Complex Disease Management Concentrates Treatment Expenditure Hospitals accounted for the largest share of the Necrotizing Autoimmune Myositis Market, representing approximately 51% of the global market, valued at USD 352.92 million in 2025, and are projected to expand at a CAGR of 8.05% during 2026–2032. Hospital-based treatment remains critical for patients with immune-mediated necrotizing myopathy (IMNM) who require specialized diagnostic evaluations, intravenous immunoglobulin (IVIG) therapy, high-dose corticosteroids, and intensive management of severe muscle weakness. Access to neurologists, rheumatologists, and multidisciplinary care teams reinforces hospitals' leading position in managing complex cases. Fastest-Growing Subsegment: Infusion Centers — Outpatient Immunotherapy Expands Specialty Treatment Capacity Infusion centers play a critical role in treating patients with Immune-Mediated Necrotizing Myopathy (IMNM), also known as Necrotizing Autoimmune Myositis, particularly those requiring intravenous immunoglobulin (IVIG) therapy and recurring immunomodulatory treatment. Infusion centers accounted for an estimated 17% of the global market, equivalent to USD 117.64 million in 2025, and are projected to register the fastest CAGR of 12.85% during 2026–2032. Increasing use of IVIG for severe or refractory cases and the need for repeated treatment cycles support their expanding role in long-term disease management. By Geography: North America Leads as Asia-Pacific Expands Specialist Diagnosis and Treatment Largest Region: North America — Specialty Treatment Infrastructure Supports Revenue Leadership North America holds the largest share of the global Necrotizing Autoimmune Myositis Market, accounting for approximately 42% in 2025, with an estimated market value of USD 290.64 million. The regional market is projected to expand at a CAGR of 8.08% during 2026–2032. Immune-Mediated Necrotizing Myopathy (IMNM), historically known as Necrotizing Autoimmune Myositis or Necrotizing Autoimmune Myopathy (NAM), remains a rare but increasingly recognized autoimmune muscle disorder. Improved diagnostic capabilities, specialized neuromuscular care, and wider access to immunosuppressive therapies support regional market expansion. Fastest-Growing Region: Asia-Pacific — Expanding Specialist Diagnosis Creates New Revenue Opportunities Asia-Pacific Necrotizing Autoimmune Myositis Market accounted for an estimated 21% of the global market, valued at USD 145.32 million in 2025, and is projected to register the fastest regional CAGR of 11.08% during 2026–2032. The growing adoption of standardized diagnostic criteria, clinical treatment guidelines, and specialized management strategies for Immune-Mediated Necrotizing Myopathy (IMNM) is improving disease identification across the region. Expanding access to neuromuscular specialists, autoantibody testing, and immunosuppressive therapies is strengthening diagnosis and treatment pathways, particularly in China, Japan, and South Korea. How Are Emerging Targeted Therapies and CAR T-Cell Technologies Transforming Treatment Opportunities in the Necrotizing Autoimmune Myositis Market? FcRn-targeting therapies are emerging as a promising treatment option for patients with immune-mediated necrotizing myopathy (IMNM). In August 2026, argenx announced positive Phase 3 ALKIVIA trial results for VYVGART Hytrulo (efgartigimod), a subcutaneous therapy designed to reduce disease-causing IgG antibodies. The study enrolled 175 patients with IMNM and dermatomyositis, with the combined treatment population demonstrating a 15.4-point greater improvement in Total Improvement Score than placebo at Week 52 (p=0.0011). Among IMNM patients specifically, the treatment achieved a 14.8-point improvement advantage (p=0.0048). These findings represent a significant clinical milestone for a disease without an approved targeted treatment and create a potential new revenue opportunity, subject to regulatory approval. CAR T-cell therapy is also advancing as an investigational option for treatment-resistant disease. Cabaletta Bio is developing rese-cel (CABA-201), an engineered CD19-directed CAR T-cell therapy designed to eliminate B cells involved in autoimmune activity. A published 2024 case study involving an IMNM patient reported reduced creatine kinase levels and improved muscle strength following treatment, with peripheral B-cell depletion achieved by Day 15. The patient experienced no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Although these findings involve a single patient, they provide early clinical evidence supporting further investigation. In January 2026, Cabaletta Bio also outlined plans for a 17-patient registrational myositis cohort, with a targeted biologics license application submission in 2027. Which Companies Are Leading Innovation in the Necrotizing Autoimmune Myositis Market? argenx — Leading Development of FcRn-Targeted Therapy for IMNM argenx is among the most clinically advanced developers of targeted IMNM treatments, with its investigational FcRn antagonist VYVGART Hytrulo (efgartigimod). On August 17, 2026, the company announced positive Phase 3 ALKIVIA results from a trial involving 175 patients with immune-mediated necrotizing myopathy and dermatomyositis.The result strengthens the company's potential position in disease-specific immunotherapy, although IMNM-specific commercialization remains subject to regulatory approval. Cabaletta Bio — Advancing CD19-Directed CAR T-Cell Therapy for Refractory IMNM Cabaletta Bio is developing resecabtagene autoleucel (rese-cel, formerly CABA-201), a CD19-directed CAR T-cell therapy designed to reset autoimmune B-cell activity. Its RESET-Myositis Phase 1/2 program included six IMNM patients in clinical data presented during 2025–2026. Company-reported baseline data indicated that 83% of these IMNM patients had previously received IVIG and 83% had received rituximab, reflecting a difficult-to-treat population. Earlier published evidence in the first IMNM patient showed reduced creatine kinase levels, improved strength, and complete peripheral B-cell depletion by Day 15. The program could create a specialized treatment opportunity for refractory disease, although its clinical evidence remains early-stage. Priovant Therapeutics — Developing TYK2/JAK1 Inhibition for Related Autoimmune Myositis Priovant Therapeutics, established through Roivant Sciences and Pfizer, developed brepocitinib, an oral TYK2/JAK1 inhibitor. Its Phase 3 VALOR trial enrolled 241 dermatomyositis patients across 90 clinical sites, with the 30 mg dose demonstrating a 15.3-point greater improvement in Total Improvement Score versus placebo at Week 52 (p less than 0.001). On August 27, 2026, Priovant announced FDA approval of LISRAYA (brepocitinib) for adults with dermatomyositis. This establishes Priovant as an important competitor in the broader autoimmune myositis field, but the approval and trial results do not establish efficacy or approval in IMNM. Other Companies and Their Roles in the Market: Abcuro: Developing ulviprubart (ABC008), a KLRG1-targeting monoclonal antibody for inclusion body myositis; its Phase 2/3 MUSCLE study did not meet its primary endpoint in February 2026, and the program is not IMNM-specific. Pfizer: Co-established Priovant Therapeutics and contributed to the development of brepocitinib for autoimmune indications, including dermatomyositis. Novartis: Has a broader immunology and autoimmune therapeutics portfolio, but a dedicated late-stage IMNM treatment program was not verified in the reviewed sources. Bristol Myers Squibb: Participates in broader autoimmune drug development, although a direct commercial or late-stage IMNM-specific product position was not established. Zai Lab: Holds Greater China development and commercialization rights for VYVGART products through its agreement with argenx and supported Chinese patient recruitment in the ALKIVIA trial. Analyst Commentary: How Will Clinical Evidence and Targeted Therapies Shape the Necrotizing Autoimmune Myositis Market? The necrotizing autoimmune myositis market is moving toward more targeted immune modulation as conventional immunosuppressive treatments continue to leave many patients with persistent muscle weakness and recurring disease activity. The most significant opportunity lies in therapies that deliver sustained muscle recovery, reduce long-term corticosteroid dependence, and improve outcomes in treatment-resistant patients. FcRn inhibitors and CAR T-cell therapies could reshape treatment approaches, particularly for severe autoimmune disease. However, high treatment costs, limited patient populations, and reimbursement challenges remain important commercial barriers. Long-term market growth will increasingly depend on demonstrating durable clinical benefits, improving access to advanced therapies, and reducing the burden of repeated treatment. Necrotizing Autoimmune Myositis Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 692.0 Million Revenue Forecast in 2032 USD 1,257.6 Million Overall Growth Rate CAGR of 8.91% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Disease Type, By Treatment Type, By Drug Class, By Diagnosis, By Route of Administration, By End User, By Geography By Disease Type Anti-HMGCR, Anti-SRP, Seronegative IMNM By Treatment Type IVIG Therapy, Immunosuppressive Therapy, Biologic Therapy, Corticosteroid Therapy By Drug Class Immunoglobulins, Immunosuppressants, Monoclonal Antibodies, Corticosteroids By Diagnosis Autoantibody Testing, CK Testing, Muscle Biopsy, MRI, EMG By Route of Administration Intravenous, Oral, Subcutaneous By End User Hospitals, Rheumatology Clinics, Infusion Centers, Neurology Clinics By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Increasing recognition and diagnosis of immune-mediated necrotizing myopathy, sustained demand for IVIG and immunosuppressive therapies, growing use of anti-HMGCR and anti-SRP autoantibody testing, rising adoption of biologic therapies for refractory disease, development of FcRn-targeting therapies, advancement of CD19-directed CAR T-cell approaches, expansion of specialist neuromuscular care, increasing infusion-center utilization, and growing demand for targeted treatment options for persistent muscle weakness and treatment-resistant disease Customization Option Available upon request Frequently Asked Question About This Report Q1. What are the main factors driving growth in the market? A1. Growth is being supported by earlier diagnosis, repeated use of IVIG and immunosuppressive therapies, and increasing recognition of treatment-resistant patients. Emerging targeted biologics are also creating new revenue opportunities. Q2. What are the key trends shaping the industry? A2. The industry is moving toward FcRn inhibitors, monoclonal antibodies, subcutaneous immunoglobulin, and CAR T-cell approaches. These therapies aim to reduce dependence on long-term corticosteroids and improve outcomes in severe disease. Q3. Why is IVIG therapy important in the market? A3. IVIG remains a major treatment option for patients with severe muscle weakness and inadequate responses to corticosteroids. Repeated infusion requirements also create recurring treatment demand across hospitals and infusion centers. Q4. How is autoantibody testing influencing the industry? A4. Autoantibody testing helps identify anti-HMGCR and anti-SRP disease subtypes and supports more precise treatment decisions. Wider testing is also improving recognition of immune-mediated necrotizing myopathy in specialist settings. Q5. What emerging therapies could reshape the market? A5. FcRn-targeting therapies and CD19-directed CAR T-cell treatment could significantly change future care. Early and late-stage studies suggest potential benefits in reducing disease activity and improving muscle strength in difficult-to-treat patients. Q6. Why are infusion centers becoming more important in the industry? A6. Infusion centers are expanding because many patients require repeated IVIG or biologic treatment outside the inpatient hospital setting. Their role is increasing as long-term outpatient immunotherapy becomes more common. Q7. What factors could limit wider market expansion? A7. High treatment costs, small patient populations, reimbursement challenges, and limited access to specialist care can restrict adoption. New therapies will also need strong evidence of durable clinical benefit before widespread use. Q8. Which region is expected to record the fastest growth in the industry? A8. Asia-Pacific is projected to record the fastest regional CAGR of 11.08% during 2026–2032. Growth is supported by improving specialist diagnosis, greater access to autoantibody testing, and wider availability of advanced immunotherapies. Sources: Mayo Clinic/NIH – IMNM Prevalence of 1.85 per 100,000 Adults Aged ≥50 in Olmsted County, Minnesota NIH/PMC – IMNM Incidence and Prevalence Study UK–Australian 2025 Study – 109 Anti-HMGCR IMNM Patients; 96.7% Prednisolone, 72.5% Methotrexate, 45.7% IVIG and 17.1% Rituximab PubMed – Anti-HMGCR IMNM Multicentre Cohort Study Clinical Treatment Review – IVIG, Rituximab, Corticosteroids and Steroid-Sparing Immunosuppressants in IMNM PubMed – Management of Immune-Mediated Necrotizing Myopathy argenx – Phase 3 ALKIVIA: 175 Patients; 15.4-Point Overall TIS Advantage and 14.8-Point Advantage in IMNM argenx – Positive Phase 3 ALKIVIA Results PubMed – First IMNM Patient Treated With CD19 CAR T Therapy (CABA-201/rese-cel): CK Reduction, Strength Improvement and B-Cell Depletion by Day 15 PubMed – CD19 CAR T Therapy in IMNM Cabaletta Bio – rese-cel Myositis Program; Planned 17-Patient Registrational Cohort and 2027 BLA Submission Cabaletta Bio – 2026 Strategic Priorities U.S. FDA – LISRAYA (Brepocitinib) Approved August 27, 2026 for Adult Dermatomyositis FDA – LISRAYA Approval 2025 Systematic Review – Anti-HMGCR/Anti-SRP IMNM, IVIG, Rituximab and Emerging FcRn-Directed Treatment Approaches PubMed – IMNM Antibody-Specific Mechanisms and Treatment Outcomes Table of Contents - Global Necrotizing Autoimmune Myositis Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Disease Type, Treatment Type, Drug Class, Diagnosis, Route of Administration, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Disease Type, Treatment Type, Drug Class, Diagnosis, Route of Administration, End User, and Geography Clinical Evidence and Disease Recognition: Mayo Clinic Prevalence Study (2022) and International Anti-HMGCR IMNM Cohort (2025) Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Disease Type, Treatment Type, Drug Class, Diagnosis, Route of Administration, and End User Regional Market Share Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Investment Opportunities in the Necrotizing Autoimmune Myositis Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in IVIG Therapy, Immunosuppressive Therapy, Targeted Biologics, Monoclonal Antibodies, Advanced Autoantibody Diagnostics, and Long-Term Disease Management Investment Opportunities in FcRn-Targeting Therapies and B-Cell-Directed CAR T-Cell Technologies Following Clinical Developments in 2026 Commercialization Opportunities Associated with Emerging Targeted Therapies and Potential Regulatory Milestones in 2027 Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Clinical and Commercial Importance of Necrotizing Autoimmune Myositis and Immune-Mediated Necrotizing Myopathy Role of Anti-HMGCR, Anti-SRP, and Seronegative Disease Recognition in Diagnosis and Treatment Selection Historical Disease Recognition and Prevalence Evidence from the Mayo Clinic Study (2022) International Patient Identification and Treatment Utilization Evidence from the UK–Australian Study (2025) Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Clinical Literature Review, Autoantibody-Based Disease Classification, and Treatment Utilization Assessment Evaluation of Historical Market Trends (2019–2024), Base Year Market Estimates (2025), and Market Forecasts (2026–2032) Assessment of Approved Treatments, Off-Label Treatment Practices, Investigational Biologics, and Emerging Cell Therapies Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approval, Clinical Evidence, and Reimbursement Factors Role of IVIG, Corticosteroids, Immunosuppressants, and Biologic Therapies in Long-Term Disease Management Rising Recognition of Anti-HMGCR, Anti-SRP, and Seronegative Immune-Mediated Necrotizing Myopathy Increasing Need for Advanced Autoantibody Testing, Creatine Kinase Assessment, Muscle Biopsy, MRI, and EMG Persistent Muscle Weakness, Treatment Resistance, and Long-Term Immunosuppressive Treatment Requirements Impact of High-Cost Immunoglobulin Treatments, Biologic Access, and Infusion-Center Availability Emerging Treatment Opportunities from FcRn-Targeting Therapies and CAR T-Cell Research in 2024, 2025, and 2026 Global Necrotizing Autoimmune Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type: Anti-HMGCR Anti-SRP Seronegative IMNM Market Analysis by Treatment Type: IVIG Therapy Immunosuppressive Therapy Biologic Therapy Corticosteroid Therapy Market Analysis by Drug Class: Immunoglobulins Immunosuppressants Monoclonal Antibodies Corticosteroids Market Analysis by Diagnosis: Autoantibody Testing CK Testing Muscle Biopsy MRI EMG Market Analysis by Route of Administration: Intravenous Oral Subcutaneous Market Analysis by End User: Hospitals Rheumatology Clinics Infusion Centers Neurology Clinics Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Necrotizing Autoimmune Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Treatment Type, Drug Class, Diagnosis, Route of Administration, and End User Regional Diagnosis and Treatment Trends, Including Specialist Neuromuscular Care and IVIG Utilization Country-Level Breakdown: United States Canada Mexico Europe Necrotizing Autoimmune Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Treatment Type, Drug Class, Diagnosis, Route of Administration, and End User Regional Clinical Research, Autoantibody Diagnostic Adoption, Biologic Access, and Reimbursement Trends Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Necrotizing Autoimmune Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Treatment Type, Drug Class, Diagnosis, Route of Administration, and End User Regional Trends in Specialist Diagnosis, Anti-HMGCR and Anti-SRP Testing, Immunoglobulin Access, and Targeted Treatment Adoption Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Necrotizing Autoimmune Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Treatment Type, Drug Class, Diagnosis, Route of Administration, and End User Regional Trends in Rare Autoimmune Disease Recognition, Specialty Treatment Availability, IVIG Access, and Reimbursement Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Necrotizing Autoimmune Myositis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Disease Type, Treatment Type, Drug Class, Diagnosis, Route of Administration, and End User Regional Trends in Specialist Autoimmune Care, Immunoglobulin Availability, Advanced Diagnostics, and Access to Biologic Therapies Country-Level Breakdown: GCC Countries Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: argenx Cabaletta Bio Priovant Therapeutics Abcuro Pfizer Novartis Bristol Myers Squibb Zai Lab CSL Behring Takeda Pharmaceutical Company Grifols Octapharma Competitive Landscape and Strategic Insights Benchmarking Based on Clinical Development Progress, Treatment Evidence, Immunoglobulin Portfolio, Autoimmune Disease Expertise, Regulatory Readiness, and Regional Presence Supplier Qualification and Immunoglobulin Availability Analysis Targeted Biologic Development and FcRn-Pathway Positioning CAR T-Cell Therapy Development and Clinical Evidence Assessment Clinical Differentiation Across Anti-HMGCR, Anti-SRP, and Seronegative IMNM Assessment of Rituximab and Other Monoclonal Antibody Treatment Strategies in Refractory Disease Competitive Analysis of Autoantibody Testing, CK Testing, Muscle Biopsy, MRI, and EMG Clinical Evidence and Pipeline Developments Reported in 2024, 2025, and 2026 Potential Regulatory and Commercialization Milestones Associated with the 2027 Development Outlook Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Disease Type, Treatment Type, Drug Class, Diagnosis, Route of Administration, End User, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Treatment Developers and Immunoglobulin Suppliers Treatment Utilization Trends Across IVIG Therapy, Immunosuppressive Therapy, Biologic Therapy, and Corticosteroid Therapy Diagnostic Pathway Assessment Across Autoantibody Testing, CK Testing, Muscle Biopsy, MRI, and EMG Regional Treatment Access and Reimbursement Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Disease Type, Treatment Type, Drug Class, Diagnosis, Route of Administration, and End User (2025 vs. 2032) Global Necrotizing Autoimmune Myositis Ecosystem and Treatment Value Chain Analysis Anti-HMGCR, Anti-SRP, and Seronegative IMNM Disease Classification and Diagnostic Pathways IVIG, Immunosuppressive Therapy, and Targeted Biologic Treatment Pathways